1
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      An Optimized Surfactant-Based PEG-PLCL In Situ Gel Formulation For Enhanced Activity Of Rosuvastatin In Poloxamer-Induced Hyperlipidemic Rats

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Injectable in situ gel (ISG) systems suffer from high initial drug release that may result in toxic effects.

          Objective

          This work aimed to develop an injectable sustained release rosuvastatin (RSV) ISG formulation with minimum initial drug burst and improved hyperlipidemic efficacy.

          Methods

          Six formulation factors that affect RSV release after 0.5, 2 and 24 hrs have been screened and the significant ones were optimized utilizing an experimental design tool. The optimum ISG formulation components were physicochemically characterized. Kinetic treatment, dissolution efficiency and mean dissolution time were investigated for the developed ISG formulations. Pharmacodynamic effects of the optimized ISG formulation were studied and compared to ISG formulation loaded with free RSV and to a marketed oral drug product.

          Results

          The concentration polylactide- co-ε-caprolactone (25: 75), the surfactant hydrophilic lipophilic balance (HLB) and the ratio of surfactant to polyethylene glycol 400 were significantly affecting the release of RSV during the first 24 h. Physicochemical characterization demonstrated complete dispersion of RSV in the polymeric matrix with slight changes in the drug crystalline structure. The optimized formulation demonstrated acceptable syringeability, good flow rate and was able to extend the in vitro drug release for 34 days. The ISG formulations complied with Weibull model. Pharmacodynamic study revealed a sustained reduction in the lipid profile that lasted for 21 days with a marked decrease in the lipid level during the first 24 hrs from the ISG system loaded with free RSV.

          Conclusion

          The optimized RSV ISG formulation could be considered a promising strategy due to a reduction in dosing frequency and enhancement in hypolipidemic efficacy.

          Related collections

          Most cited references 44

          • Record: found
          • Abstract: not found
          • Article: not found

          Mechanisms of solute release from porous hydrophilic polymers

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            On the importance and mechanisms of burst release in matrix-controlled drug delivery systems.

            Although the significance of burst release in controlled delivery systems has not been entirely ignored, no successful theories have been put forth to fully describe the phenomenon. Despite the fact that the fast release of drug in a burst stage is utilized in certain drug administration strategies, the negative effects brought about by burst can be pharmacologically dangerous and economically inefficient. Therefore a thorough understanding of the burst effect in controlled release systems is undoubtedly necessary. In this article, we review experimental observations of burst release in monolithic polymer controlled drug delivery systems, theories of the physical mechanisms causing burst, some of the unique ideas used to prevent burst, and the treatment of burst release in controlled release models.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Analysis of Fickian and non-Fickian drug release from polymers.

               N A Peppas (1984)
                Bookmark

                Author and article information

                Journal
                Drug Des Devel Ther
                Drug Des Devel Ther
                DDDT
                dddt
                Drug Design, Development and Therapy
                Dove
                1177-8881
                03 December 2019
                2019
                : 13
                : 4035-4051
                Affiliations
                [1 ]Department Of Pharmaceutics, Faculty Of Pharmacy, King Abdulaziz University , Jeddah, Kingdom of Saudi Arabia
                [2 ]Department Of Pharmaceutics And Industrial Pharmacy, Faculty Of Pharmacy, Al-Azhar University , Cairo 11651, Egypt
                Author notes
                Correspondence: Tarek A Ahmed, Department Of Pharmaceutics, Faculty Of Pharmacy, King Abdulaziz University , PO. Box 80200, Jeddah 21589, Kingdom of Saudi Arabia Email tabdelnapy@kau.edu.sa
                Article
                224442
                10.2147/DDDT.S224442
                6904902
                31839704
                © 2019 Ahmed et al.

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                Page count
                Figures: 7, Tables: 5, References: 46, Pages: 17
                Categories
                Original Research

                Comments

                Comment on this article